MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company`s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator(TM) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. The Company is majority-owned by Nanostart AG. it has a subsidiary MT MedTech Engineering GmbH.